Lilly Official Says New Technologies Pose Challenges for Rx/Dx Codevelopment

At a conference this week, an Eli Lilly official said that increasingly novel test platforms may pose challenges for drug developers in terms of regulatory approval and physician adoption.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.